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Summary 
Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2, has 
demonstrated encouraging anti-cancer activity in gastric cancer within both in vitro and in vivo 
models. Its therapeutic efficacy, tolerability and safety have been evaluated in one Phase II and one 
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Phase III study in metastatic/advanced gastric cancer. In this review, we focus on the mechanism of 
action of apatinib, its pharmacokinetic profile and its clinical activity in the treatment of 
advanced/metastatic gastric cancer. 
Keywords: Gastric cancer, Apatinib, VEGFR2, angiogenesis, chemotherapy 
1. Introduction
Gastric cancer (GC) is the fifth most common cancer worldwide and, despite improvements in the 
treatment of this disease, GC is the third most common cancer-related cause of death in the world 
[1]. It is estimated that in the entire world population, about 1 million people are diagnosed with GC 
annually, and approximately half of these cases are in China [1]. In the metastatic setting, 
chemotherapy provides only palliation of symptoms and improvement in the quality of life 
compared to best supportive care, and has only a modest impact on survival [2,3]. In general, 
regimens which combine a fluoropyrimidine with a platinum-based agent are the most widely 
accepted as a standard first-line therapy [4,5]. A three-drug chemotherapy regimen, with the 
addition of an anthracycline or docetaxel, may represent a possible option for patients who can 
tolerate more aggressive chemotherapy. Second lines of therapy may include irinotecan and 
taxanes, however their use is limited only to patients with an adequate performance status. 
Unfortunately, after failure of second-line treatment, the results of further lines of chemotherapy are 
disappointing (based on results in human epidermal receptor 2 (HER-2) positive GC), and no 
chemotherapeutic agents showed a clear benefit in prolonging survival [6]. Therefore, the discovery 
of novel, effective and safe treatment options is an unmet clinical need for metastatic GC.  
Apatinib, also known as YN968D1, is a novel receptor tyrosine kinase inhibitor selectively 
targeting the intracellular ATP-binding site of vascular endothelial growth factor receptor 2 
(VEGFR2) [7,8]. Evidence that apatinib treatment provides a clinical benefit in patients with 
metastatic GC is now available. This review will examine the role of apatinib in GC, with 
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references to its proposed mechanism of action, as well as its efficacy, safety, and tolerability in 
clinical trials.  
2. Body of review
2.1 Overview of the market 
Treatment of metastatic GC is still a real clinical challenge. Although several chemotherapeutic 
agents, including platinum-based compounds (cisplatin and oxaliplatin), fluoropyrimidines (5-
fluorouracil; capecitabine and S-1 in Asiatic countries), taxanes (docetaxel and paclitaxel), and the 
anthracyclines, such as epirubicin, are currently available for first- and second-line therapy in 
metastatic disease, the prognosis still remains poor with a low percentage of long term survivors 
and an overall survival that does not exceed 12 months [4,9,10]. More recently, biological therapies 
have become available for the treatment of metastatic GC [11]. Trastuzumab, a monoclonal 
antibody against HER-2, is approved for the 20% of patients with  HER-2 positive GC tumours 
[12]. Moreover, ramucirumab, a monoclonal antibody targeted against VEGFR2, has shown a 
survival benefit as a second line treatment option in those metastatic GC patients who progressed on 
fluoropyrimidine- or platinum-based first-line chemotherapy [12-14]. 
Unfortunately, very few data are available on the use of chemotherapy in the third-line setting: only 
taxane or  irinotecan-based regimens have shown modest effects on survival with a very low rate of 
response [15-16]. Recent reports suggest that regorafenib, a pan-receptor tyrosine kinase inhibitor, 
may have some activity in GC [17]. The INTEGRATE study showed a progression free survival 
advantage for regorafenib compared to placebo in refractory advanced GC patients who had already 
progressed after first and second line therapy [17]. Due to these newly available treatment options, 
the number of patients with metastatic GC who have been treated with several lines of therapy will 
increase. Amongst the newly available biological therapies available for the treatment of GC, apatinib has 
shown promising activity [18] and will be the subject of this review.  
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2.2 Introduction to the drug 
2.2.1 Chemistry 
Apatinib is an orally bioavailable small-molecule anti-angiogenic agent, with a molecular weight of 
493.58 Da, that  potently inhibits VEGFR2, whilst also have some activity for inhibition of the 
platelet-derived growth factor receptor-β (PDGFR-β), c-kit, and c-src [18]. The molecular formula 
of apatinib is C25H27N5O4S, and chemical formula is N-[4-(1-cyano-cyclopentyl)phenyl]-2-(4-
pyridylmethyl) amino-3-pyridine carboxamide, which is shown in [19] Figure 1. 
2.2.2 Mechanism of action 
VEGFR2 is stimulated by VEGF molecules that induce dimerization of the receptor and a 
subsequent auto-phosphorylation. VEGFR2 activation stimulates several downstream signalling 
pathways, including the Raf/MEK/ERK1/2, the p38-MAPK and the PI3K/AKT/mTOR pathway 
[20,21]. VEGF stimulation of the receptor induces the sprouting of new blood vessels from pre-
existing vessels [22]. The mechanism of action of apatinib is mediated by its binding to the 
intracellular ATP-binding site of VEGFR2 receptor (Figure 2)  which blocks its phosphorylation 
and subsequently the downstream pro-angiogenic signalling. Apatinib displays both anti-angiogenic 
and anti-tumour activity in preclinical models, including a stomach cancer xenograft model [18].  
2.2.3 Pharmacokinetics and metabolism 
The pharmacokinetics and metabolism of apatinib have been studied. After administration of 
apatinib to human subjects, the time to maximum plasma concentration level was ~4 hours after 
dosing and the mean half-life was 9 hours [23]. In three different dosing regimens (500, 750 and 
800), a dose-dependent  Cmax and AUC24 were observed with Cmax of 1,521, 2,379, and 2,833 
ng/mL and AUC24 of 11,295, 18,172, and 21,975 ngh/mL, respectively [24]. Further analysis 
suggested no accumulation of drug following 56 days of once-a-day administration of 750 mg 
apatinib [23]. The primary routes of apatinib biotransformation include E- and Z-cyclopentyl-3-
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hydroxylation, N-dealkylation, pyridyl-25-N-oxidation, 16-hydroxylation, dioxygenation, and O-
glucuronidation after 3-hydroxylation 15DDT. The major circulating metabolite was the 
pharmacologically inactive E-3-hydroxy-apatinib-O-glucuronide (M9-2) [24]. The primary 
metabolisers of apatinib are CYP3A4/5 and UGT2B7 is the main enzyme responsible for M9-2 
formation [25]. The total recovery of the administered dose was 76.8% within 96 hours post-dose, 
with 69.8% and 7.02% of the administered dose excreted in feces and urine, respectively [24,25]. 
2.3 Clinical efficacy 
2.3.1 Phase I study 
The clinical development of apatinib has been carried out mostly in China. In 2010, a phase I study 
was performed to determine the pharmacological activity and the maximum tolerated dose (MTD) 
of apatinib for patients with advanced solid tumors [23]. Thirty-four patients enrolled in the study 
had gastrointestinal tract-related tumors. The study established that the MTD for apatinib was 850 
mg once daily. Moreover, a significant antitumor activity was also observed in patients with 
measurable lesions; the 7 patients achieving partial response were mainly those with GC tumors. 
The most frequently observed drug-related adverse events were hypertension, proteinuria, and 
hand-foot syndrome (which are all common drug class effects of oral VEGFR2 tyrosine kinase 
inhibitors) and they were clinically manageable.  
2.3.2 Phase II study 
A single phase II study investigated apatinib versus placebo in heavily pre-treated metastatic GC 
patients [26]. All the enrolled patients had progressed after two lines of therapy and about 30% 
were treated with ≥3 lines of prior therapy. Two schedules of apatinib were evaluated: the 850 mg 
once daily regimen and the 425 mg twice daily regimen. The primary end-point of this study was 
progression free survival (PFS). One hundred and forty one patients were divided as follow: 48 in 
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the placebo group, 47 in the arm with 850 mg apatinib once daily and 46 in the arm with 425 mg 
apatinib twice daily. The percentage of patients receiving at least two cycles of treatment was 50% 
in the placebo group, 74.5% in the 850 mg group and 69.6% in the 425 mg group [26]. Apatinib 
treatment significantly improved the PFS when compared with placebo. PFS was 3.67 months and 
3.20 months for patients who received apatinib 850 mg once daily and 425 mg twice daily, 
respectively, and 1.40 months for patients who received placebo. Multivariate Cox regression 
analysis showed that PFS was significantly different between apatinib versus placebo without any 
significant difference between the two schedules of apatinib. The median OS values were 4.83 
months and 4.27 months, for patients who received 850 mg once daily apatinib and 425 mg twice 
daily apatinib, respectively, and 2.50 months in the placebo group. The overall response rate and 
disease control rate favoured the arms containing apatinib versus placebo.  
2.3.3 Phase III studies 
Based on the results of the phase II trial [26], a randomized, double-blind, placebo-controlled phase 
III trial of apatinib in heavily pre-treated advanced or metastatic gastric or gastroesophageal 
junction cancer was conducted [27]. Two hundred and sixty seven patients were enrolled; 176 were 
assigned to the apatinib group and 91 were assigned to the placebo group. The primary end-points 
were OS and PFS. Patients in the apatinib group received a median of 2.9 cycles of therapy, and 
72% of patients were treated with two or more cycles of therapy. Patients in the placebo group 
received a median of 1.89 cycles of placebo, and 58% of patients were treated with two or more 
cycles of placebo (P=0.0028) [27]. The disease control rate was significantly improved with 
apatinib compared to placebo (31.82% versus 10.99%; P<0.001). The overall response rate was 
1.7% with apatinib versus 0% with placebo. The median PFS was also significantly longer (2.6 vs 
1.8 months; HR=0.444; P<0.001). The median OS was 6.5 months with apatinib versus only 4.7 
months with placebo (HR=0.709, 95% CI, 0.537-0.595, P=0.149). The quality of life was evaluated 
using the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTCQLQ-C30) at three different time points (baseline and end of cycles 
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two and three). The analysis showed no significant differences between the two groups at any time 
point (P>0.05).  
3. Safety and tolerability 
In the phase I trial [23], the most frequently observed drug-related adverse events with apatinib 
were hypertension (69.5%, 29 grade 1–2 and three grade 3–4), proteinuria (47.8%, 16 grade 1–2 
and six grade 3–4), and hand–foot syndrome (45.6%, 15 grade 1–2 and six grade 3–4). Eighteen 
patients had a dose reduction due to different toxicities. In the phase II trial, grade 3-4 adverse 
events occurred in more than 5% of patients [26] and the most frequent were: hand-foot syndrome, 
hypertension, thrombocytopenia, anemia, diarrhea, and liver toxicity (mainly, elevation of 
aminotransferase and bilirubin levels). The most frequently observed grade 3-4 adverse events were 
hand-foot syndrome and hypertension detected in the 10% of the patients. Fatigue was a common 
adverse event, affecting a total of 10.4%, 17.0%, and 15.2% of patients receiving placebo, apatinib 
850 mg once daily, or apatinib 425 mg twice daily, respectively.  
In the phase III trial [27], dose modifications resulting from toxicity were more common in the 
apatinib arm compared to the placebo arm (21.0% versus 3.3%, respectively). The main reasons for 
dose reduction were hand-foot syndrome, proteinuria, and hypertension. A grade 3-4 hand-foot 
syndrome occurred in 8.5% and 0% of patients in the apatinib and placebo group, respectively 
(P=0.0032). Grade 3-4 hypertension and proteinuria occurred in 4.5% and 2.3% of patients in the 
apatinib group, but was 0% in the placebo group. Grade 3-4 neutropenia, transaminase elevation 
and hypophosphatemia were also increased in the apatinib arm. Details of adverse events from these 
studies are provided in Table 1. 
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4. Regulatory affairs
Based on the data from the phase III study, apatinib was approved in October 2014 by the China 
Food and Drug Administration (CFDA) for patients with metastatic gastric or gastroesophageal 
junction adenocarcinoma after the second-line of chemotherapy [28]. 
5. Conclusion
Apatinib is a novel, orally bioavailable small-molecule tyrosine kinase inhibitor of VEGFR2 that 
appears to be a promising agent in the treatment of a variety of tumor types including metastatic 
GC. However, although the initial clinical results are promising, it should be stated that the small 
number of patients recruited in these clinical trials does preclude definitive conclusions at the 
current time. Nonetheless, apatinib compared to placebo has been shown to improve overall 
survival, progression free survival and response rate in heavily pre-treated patients (i.e. those 
receiving more than 2 lines of prior therapy). Tumor angiogenesis is a crucial process in cancer 
development and progression [29], especially in gastro-intestinal tumors [30], thus targeting it could 
be an interesting and beneficial therapeutic option. At this point, it is worth recapping what is 
known regarding other anti-angiogenic agents in GC. The monoclonal anti-VEGF antibody 
bevacizumab, in combination with chemotherapy, did not met its primary endpoint to improve 
survival in metastatic GC [31]. Ramucirumab is a humanized monoclonal antibody against 
VEGFR2 which prevents VEGF ligand binding and receptor-mediated pathway activation in 
endothelial cells [11]. Ramucirumab is approved for patients with advanced gastric or 
gastroesophageal junction cancer that experienced progression after first-line chemotherapy [11]. 
Approval was based on gains in overall survival when the drug was administered either alone or in 
combination with paclitaxel in phase III studies [11]. Of note, although ramucirumab and apatinib 
target the same signalling pathway, they have different mechanisms of action. However, their 
efficacy in GC suggests an important role for VEGF receptor signalling in GC. Nonetheless the 
clinical advantage seems modest (around two months gain in both progression free survival and 
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overall survival). Since apatinib is the first tyrosine-kinase inhibitor shown to be effective in 
metastatic GC, the continued clinical exploitation of this drug for metastatic GC is warranted. 
6. Expert commentary
It should be noted that although the clinical studies performed so far support the use of apatinib in 
GC, this may be mainly due to the real absence of an efficacious treatment as a comparator. 
Therefore, the real clinical efficacy of apatinib is still to be weighed in larger trials.  
It is also important to consider whether a subset of GC patients can be selected which optimally 
respond to apatinib. The Cancer Genome Atlas Research Network (TCGA) has demonstrated a 
subset of GC with a recurrent amplification of the VEGF-A gene and with an elevated expression of 
angiogenesis-related pathways [31-34]. In addition, several trials showed that the expression of 
VEGFR2 is related to a poor prognosis in patients with metastatic GC [35]. Given the molecular 
evidence that the VEGF pathway is upregulated in only a subset of GC cancers, it may be beneficial 
to pursue predictive biomarkers for anti-VEGF pathway therapies in this cancer. This would help in 
selecting the right patients to treat with apatinib. One potential candidate for such a biomarker is the 
expression level or activation status of VEGFR2 in GC. In this context, a study of apatinib in 
patients with breast cancer showed that both hypertension and high expression of phosphorylated 
VEGFR2 could serve as potential biomarkers for treatment efficacy [36]. Unfortunately, as yet, 
there is no definitive biomarker data for apatinib in GC. 
7. Five-year view
The efficacy and safety of apatinib in metastatic GC will be evaluated in an on-going phase IV 
study (NCT02426034) already started in April 2015. A total of 2000 patients are planned to be 
enrolled. Undoubtedly, this large study will provide important information as to the clinical role of 
apatinib in the second line treatment of GC. Additional studies will investigate the role of apatinib 
as a maintenance therapy after the first line of treatment in GC. Apatinib will be also investigated in 
combination with chemotherapeutic agents such as  S-1 in the first-line of treatment or S-
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1/paclitaxel based chemotherapy in the conversion therapy of metastatic GC [37]. Details of these 
trials are provided in Table 2. 
 
 
Key issues 
• Apatinib is a novel receptor tyrosine kinase inhibitor selectively targeting the intracellular 
ATP-binding site of the vascular endothelial growth factor receptor 2 (VEGFR2) 
• Apatinib compared to placebo has been shown to improve survival, progression free 
survival and response rate in heavily pre-treated GC patients.  
• The toxicities of apatinib were tolerable or clinically manageable. Hypertension, hand-and-
foot syndrome, proteinuria, fatigue, anorexia, and elevated aminotransferase were the most 
commonly observed adverse events. 
Information resources 
Basic information on the chemistry and properties of apatinib can be obtained from the online Salix 
Pharmaceuticals drug information or from the PubChem website. For an overview of the diagnosis 
and management of GC, please see the American College of Gastroenterology. For references 
directly pertaining to the action or use of apatinib please see the recommended references below.  
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Figure 1. Chemical structure of apatinib. 
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Figure 2. Mechanism of action of apatinib 
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Table 1. Adverse events in clinical trials of apatinib for gastric cancer. 
 
 
 
 
  
Adverse event 
Numbers  
(%) 
Li et al. 2013 Li et al. 2016 
Apatinib 425 mg 
(n=46) 
Apatinib 850 mg 
(n=47) 
Placebo 
(n=48) 
Apatinib 
(n=176) 
Placebo 
(n=91) 
Any grade Grade 3-4 Any grade Grade 3-4 Any grade Grade 3-4 Any grade Grade 3-4 Any grade Grade 3-4 
Leukopenia 18 (39) 2 (4.3) 23 (49) 0 (0) 4 (8.3) 2 (4.2) 71 (40.3) 3 (1.7) 8 (8.8) 0 (0) 
Neutropenia 15 (32.6) 2 (4.3) 18 (38.3) 1 (2.1) 3 (6.3) 2 (4.2) 66 (37.5) 10 (5.7) 9 (9.9) 1 (1.1) 
Anemia 8 (17.4) 3 (6.5) 9 (19.1) 1 (2.1) 9 (18.8) 3 (6.3) 44 (25) 11 (6.3) 22 (24.2) 4 (4.4) 
Thrombocytopenia 18 (39.1) 2 (4.3) 14 (29.8) 2 (4.3) 6 (12.5) 2 (4.2) 44 (25) 5 (2.8) 6 (6.6) 1 (1.1) 
Proteinuria 16 (34.8) 2 (4.3) 13 (27.7) 1 (2.1) 6 (12.5) 0 (0) 84 (47.7) 4 (2.3) 15 (16.5) 0 (0) 
Hypertension 18 (39.1) 5 (10.9) 19 (40.4) 4 (8.5) 2 (4.2 ) 0 (0) 62 (35.2) 8 (4.5) 5 (5.5) 0 (0) 
Hand foot syndrome 21 (45.7) 6 (13) 12 (25.5) 2 (4.3) 2 (4.2) 1 (2.1) 49 (27.8) 15 (8.5) 2 (2.2) 0 (0) 
Fatigue 7 (15.2) 1 (2.1) 8 (17) 1 (2.1) 5 (10.4) 1 (2.1) 36 (20.5) 5 (2.8) 13 (14.3) 2 (2.2) 
Abdominal pain 6 (13) 1 (2.2) 4 (8.5) 0 (0) 5 (10.4) 1 (2.1) 28 (15.9) 3 (1.7) 16 (17.6) 4 (4.4) 
Diarrhea 13 (28.3) 3 (6.5) 8 (17) 1 (2.1) 2 (4.2) 0 (0) 20 (11.4) 2 (1.1) 3 (3.3) 1 (1.1) 
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Table 2. Ongoing trials with Apatinib in gastric cancer. 
Clinical trial 
identifier 
Primary Endpoint Treatment arm Patients to be 
enrolled 
Phase Setting Status 
NCT02409199 Progression free
survival 
Apatinib vs 
Docetaxel 
66 II/III Second line Recruiting
NCT02426034 Safety and efficacy Apatinib 2000 IV Second line Ongoing, but
not recruiting 
NCT02509806 Progression free
survival 
Apatinib 48 II/III Maintenance therapy 
after first-line 
chemotherapy 
Not yet open for 
recruiting 
NCT02510469 Disease free survival Apatinib 48 II/III Maintenance therapy 
after adjuvant 
chemotherapy 
Not yet open for 
recruiting 
NCT02525237 Progression free
survival; safety 
Apatinib  
plus S-1 
30 II First line Not yet open for 
recruiting 
NCT02596256 Progression free
survival 
Apatinib plus 
Docetaxel vs 
Docetaxel 
80 II Second line Not yet open for 
recruiting 
NCT02529878 Radical resection rate S1/Paclitaxel 
plus Apatinib 
30 II/III Conversion therapy* Recruiting
NCT02537171 Progression free
survival 
Apatinib 40 III Maintenance after first 
line treatment 
Recruiting 
*Patients converted from an initially unresectable GC to a resectable cancer
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